Gennao Bio Announces Oral Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting

– Presentation to showcase the broad therapeutic potential of Gennao’s non-viral gene monoclonal antibody (GMAB) platform technology to systemically deliver immunostimulatory RNAs to solid tumors –

HOPEWELL, N.J., March 8, 2022 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its proprietary, non-viral gene monoclonal antibody (GMAB) platform technology has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place April 8 – 13, 2022 in New Orleans, LA. Gennao’s GMAB platform utilizes a novel, cell-penetrating antibody to non-covalently form complexes with and systemically target and deliver effective levels of nucleic acids, including immune-stimulating synthetic RNA, to solid tumors.

The details of the oral presentation are as follows:

Title: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody

Abstract Control Number: 6710

Session Title: Immune Checkpoint and Immune Modulatory Therapy

Session Type: Minisymposium

Session Date and Time: Sunday, April 10, 2022; 3:00 p.m. – 5:00 p.m. Central Daylight Time

Presenter: Elias Quijano, Yale School of Medicine

 

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Contact

Joe Rayne
JRayne@gennao.com 
201-373-2173